Refractory ulcerative colitis:Upadacitinib versus other biologics  

作　　者：Said G Farhat Jessy G Fadel 

机构地区：[1]Department of Gastroenterology Research,Saint George University of Beirut,Beirut 00000,Lebanon [2]Dr.Sulaiman Al Habib Hospital,Dubai 00000,United Arab Emirates

出　　处：《World Journal of Clinical Cases》2024年第31期6425-6427,共3页世界临床病例杂志

摘　　要：In this editorial we comment on an article published in World Journal of Clinical Cases in 2024,in which a case of refractory ulcerative colitis(UC)was discussed based on the response to different lines of biologics.Different studies showed that different classes of biologics have their advantages and disadvantages in the treatment of refractory UC.Certain classes are superior to others and if tried earlier on would lead to a possible change in the outcome.

关 键 词：REFRACTORY Ulcerative colitis Upadacitinib USTEKINUMAB Vedolizumab 

分 类 号：R574.62[医药卫生—消化系统]